Prognostic value of RGS1 and mTOR Immunohistochemical expression in Egyptian multiple myeloma patients; A single center study.

Nora HafezLobna RefaatOmnia K ElGebalyHossam M ElhariryMohammed GhareebLamiaa A Fathalla

Published in: PloS one (2023)

RGS1 and mTOR were suggested as poor prognostic markers in MM patients, being associated with lower response rate and inferior OS. We recommend considering RGS1 and mTOR as one of the prognostic criteria in different risk stratification and staging classifications. Further trials for RGS1 and mTOR targeting in multiple myeloma are recommended.

Keyphrases

end stage renal disease
multiple myeloma
ejection fraction
newly diagnosed
cell proliferation
chronic kidney disease
prognostic factors
peritoneal dialysis
lymph node
patient reported outcomes
drug delivery
cancer therapy
patient reported
long non coding rna